Statistical Method to Analyze Data from Delayed Start Design in Parkinson’s Disease
View Presentation *Ohidul I Siddiqui, CDER, FDA Keywords: delayed start design, missing data, parkinson's disease Development of a drug that could potentially modify the course of Parkinson’s disease is extremely challenging. A design that has been proposed for such a claim is delayed start design. In this design, a comparison is made between the patients who are early randomized to treatment (early start) vs. the patients who are initially randomized to placebo are given active treatment after certain weeks (delayed start). It is hypothesized that if the early start treatment group has lower mean clinical score compared to the mean score of the delayed start treatment group at the end of study period, the drug has disease modifying benefit. In delayed start design, missing data due to dropouts are unavoidable. The missing data at the end of delayed start period are often imputed using LOCF approach. Clinical trial simulations are conducted to evaluate the statistical properties (including typ
|
Key Dates
-
April 30 - May 22, 2013
Invited Abstract Submission Open -
June 4, 2013
Online Registration Opens -
August 9 - August 23, 2013
Invited Abstract Editing -
August 23, 2013
Short Course materials due from Instructors -
August 26, 2013
Housing Deadline -
September 9, 2013
Cancellation Deadline and Registration Closes @ 11:59 pm EDT -
September 16 - September 18, 2013
Marriott Wardman Park, Washington, DC